The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 24, 2015

Filed:

Apr. 02, 2009
Applicants:

P. Martin Petkovich, Kingston, CA;

Christian F. Helvig, Markham, CA;

Joel Z. Melnick, Wilmette, IL (US);

Inventors:

P. Martin Petkovich, Kingston, CA;

Christian F. Helvig, Markham, CA;

Joel Z. Melnick, Wilmette, IL (US);

Assignees:

Opko Renal, LLC, Miami, FL (US);

Opko IP Holdings II, Inc., Grand Cayman, KY;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); G01N 33/53 (2006.01); G01N 33/573 (2006.01); A01N 45/00 (2006.01); A61K 31/00 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); A61K 31/00 (2013.01); A61K 45/06 (2013.01); G01N 33/6893 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/046 (2013.01); G01N 2800/347 (2013.01); C12Q 2600/106 (2013.01);
Abstract

Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.


Find Patent Forward Citations

Loading…